About US
Contact us
-
Merck Group granted US patent for digital-enabled supply chain security methodGerman-based Merck Group has been granted a patent for creating ‘crypto-objects’ based on artificial intelligence (AI) and blockchain that can be used to secure pharmaceutical supply chains. The pate2019/2/1
-
Pfizer CEO: It'll be 2020 before issues in sterile injectables manufacturing are resolvedIt appears it will be another hard year for U.S. hospitals to get their hands on sterile injectables as work continues at Pfizer’s troubled plant in Kansas, perhaps the largest U.S. producer of the dr2019/1/31
-
Test run of drug prices in ads exposes a loophole—and pharma's already using itIt’s no surprise that listing the high price of a drug in advertisingwould discourage consumers. But add in an offer to help cover the cost—withcopay or coupon assistance—and viewers are fine with apr2019/1/31
-
Amgen hunts for deals of all sizes to combat forthcoming sales declineA couple of Big Pharma players have come out against megamergers in recent weeks. But Amgen isn’t one of them. On Tuesday’s fourth-quarter earnings conference call, CEO Bob Bradway said his company c2019/1/30
-
Pfizer's suffering from generics, but 'innovation for growth'—not big M&A—is still the mantraPfizer’s M&A strategy is always a topic of interest, but that interest has ramped up with the company’s recent CEO switch. So far, though, new chief Albert Bourla is sticking with the company line2019/1/30
-
Biogen executives fend off Alzheimer's questions with pipeline promises, deal talkIf there’s one thing that prompts hand-wringing amongst Wall Street analysts who cover Biogen, it’s the company’s reluctance to present interim data from ongoing clinical trials of its closely watched2019/1/29
-
Novartis: Alternative payments will ‘reset the paradigm’ for covering gene, cell therapiesWhen Dave Lennon, president of Novartis unitAveXis, said in November that the company’s experimental gene therapy to treat spinal muscular atrophy (SMA) could be cost-effective at a price of $4 millio2019/1/29
-
FDA finds more issues at Lupin plant it spanked in warning letterThe FDA in 2017 ripped Indian drugmaker Lupin in a warning letter for not learning from past mistakes. In a new visit to one of the two plants cited in that letter, the FDA has again found issues. Lu2019/1/28
-
Takeda’s dengue shot, rival to Sanofi's Dengvaxia, hits the mark in massive phase 3 studyIt’s no secret Sanofi has had trouble with its world-first dengue vaccine,Dengvaxia, but that hasn't dissuaded Takeda. Its own dengue shot met its goal in a pivotal phase 3 study that covered eight co2019/1/28
-
Bayer gets with the program for Super Bowl LIII to kick off cancer testing awareness effortBayer is going to the Super Bowl. Not with some glitzy $5 million TV ad, but instead with a print ad in the official Super Bowl LIII program to launch its new awareness campaign around genomic testing2019/1/25